Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event

AUSTIN, Texas, May 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Norman LaFrance, M.D., Chief Medical Officer and Senior Vice President, will participate in the “Know All Your Treatment Options 2023” virtual educational event organized by EndBrainCancer Initiative (EBCI).

Presentation Details

Topic	A Novel Targeted Radiotherapeutic for Brain Cancer: The ReSPECT Trials
Date	Friday, May 19, 2023
Time	Event begins at 2:00 p.m. ET (11:00 a.m. PT); Dr. LaFrance to present at 3:00 p.m. ET (12:00 p.m. PT)
Access	Registration is free and must be completed by end of day Tuesday, May 16, 2023: https://lnkd.in/gArPRzCC. The event will be livestreamed on EBCI’s Facebook Page at and will be made available on its YouTube Channel two weeks following the event.

About EBCI
The EndBrainCancer Initiative | Chris Elliott Fund is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, FDA-approved treatments, devices, specialists, advanced treatments and clinical trials. We believe that IMMEDIATE ACCESS to these options provides the patient community with the best HOPE for survival and sustained quality of life. www.EndBrainCancer.org

About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.